2-Chloranyl-~{n}-[(7~{s})-2-Methyl-7-Phenyl-10-(1~{h}-1,2,3,4-Tetrazol-5-Yl)-8,9-Dihydro-6~{h}-Pyrido[1,2-A]indol-7-Yl]-4-(1,2,4-Triazol-4-Yl)benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Chloranyl-~{n}-[(7~{s})-2-Methyl-7-Phenyl-10-(1~{h}-1,2,3,4-Tetrazol-5-Yl)-8,9-Dihydro-6~{h}-Pyrido[1,2-A]indol-7-Yl]-4-(1,2,4-Triazol-4-Yl)benzamide
• 英文别名: 2-chloro-N-[(7S)-2-methyl-7-phenyl-10-(2H-tetrazol-5-yl)-8,9-dihydro-6H-pyrido[1,2-a]indol-7-yl]-4-(1,2,4-triazol-4-yl)benzamide
• 化学式: C₂₉H₂₄ClN₉O
• 分子量: 550.0
• InChiKey: TUCDMISJVGVBLL-GDLZYMKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  40
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] FACTOR IXa INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2016133793A1

  公开（公告）日：2016-08-25

  The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

  本发明提供了一种Formula I的化合物，以及包括一种或多种该化合物的药物组合物，以及使用该化合物用于治疗或预防不稳定性心绞痛、难治性心绞痛、心肌梗死、短暂性缺血性发作、心房颤动、血栓性中风、栓塞性中风、深静脉血栓形成、弥散性血管内凝血、眼部纤维蛋白堆积、以及再闭塞或再狭窄的再通血管的方法。这些化合物是选择性因子IXa抑制剂。
• Factor IXa inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10351558B2

  公开（公告）日：2019-07-16

  The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

  本发明提供了一种式I化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防不稳定型心绞痛、难治性心绞痛、心肌梗塞、短暂性脑缺血发作、心房颤动、血栓性中风、栓塞性中风、深静脉血栓形成、弥散性血管内凝血、眼部纤维蛋白堆积、再通血管的再闭塞或再狭窄的方法。这些化合物是选择性因子 IXa 抑制剂。
• FACTOR IXa INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3258929A1

  公开（公告）日：2017-12-27
• FACTOR IXA INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3258929B1

  公开（公告）日：2022-04-27
• Factor IXa Inhibitors
  申请人：MENG Dongfang

  公开号：US20180022747A1

  公开（公告）日：2018-01-25

  The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.